While we have previously demonstrated that both pro-apoptotic ASPP family members are frequently deregulated in AML, and that attenuated levels of either ASPP1 or ASPP2 correlats with an adverse outcome [9, 10], the significance of iASPP in AML is unclear. The gene discussed is TP53BP2; the disease is acute myeloid leukemia.